Physician profile
Andrew Wall
NPI 1578067021
$623.83
in general payments reported to CMS, 2019-2025
13 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $62.08 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $100.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.71 | 2025 | |
| Amgen INC. | $70.72 | 2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.07 | 2025 | Lifevest |
| Novo Nordisk INC | $59.82 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $43.73 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.28 | 2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $33.19 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.32 | 2025 | Onpattro |
| Heartflow, INC. | $24.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.79 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $20.83 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.46 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.